Fig. 3

URRCC enhances the development of progression in ccRCC in vivo. a: The in vivo effect of URRCC was evaluated in xenograft mouse models bearing tumors originating from A498 cells stably transfected with sh-URRCC or sh-control, n = 8/group; Weights of the xenografts were shown in the right. b: The in vivo effect of URRCC was evaluated in xenograft mouse models bearing tumors originating from OSRC-2 cells stably transfected with oe-URRCC or mock, n = 8/group; Weights of the xenografts were shown in the right. c: Representative images of mice in each group at 4 weeks after tail vein injections of A498 (sh-control or sh-URRCC infected) or OSRC-2 (mock or oe-URRCC infected), n = 8/group. d and e: Representative images of pulmonary metastasis in each group at 8 weeks after tail vein injections. f and g: Representative microscopic images of pulmonary metastatic lesions at 8 weeks after tail vein injection of indicated ccRCC (left). Red arrows indicate lung metastatic tumors (100×). The number of lung metastatic tumors in each group (n = 8) was calculated (right). h and i: Representative Ki67 IHC staining of pulmonary metastasis from sh-control, sh-URRCC, mock, and oe-URRCC groups (200×, 400×)